| # | Country | Total Patents | |
|---|---|---|---|
| #1 | United Kingdom | 22 | |
| #2 | WIPO (World Intellectual Property Organization) | 8 | |
| #3 | EPO (European Patent Office) | 5 | |
| #4 | Australia | 3 | |
| #5 | Canada | 3 | |
| #6 | China | 3 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Environmental technology |
| # | Technology | |
|---|---|---|
| #1 | Medical preparations | |
| #2 | Peptides | |
| #3 | Therapeutic chemical compounds | |
| #4 | Climate change adaptation technologies | |
| #5 | Microorganisms |
| # | Name | Total Patents |
|---|---|---|
| #1 | Heath Andrew | 12 |
| #2 | Heath Andrew William | 8 |
| #3 | Laing Peter | 6 |
| #4 | De Leenheer Evy | 2 |
| #5 | Lang Peter | 2 |
| #6 | Carlring Wright Jennifer | 1 |
| #7 | Carling-Wright Jennifer | 1 |
| #8 | Peter Heath Andrew Lang | 1 |
| #9 | Peter Heath Andrew Laing | 1 |
| #10 | Bacon Andrew | 1 |
| Publication | Filing date | Title |
|---|---|---|
| WO2011158019A1 | Polypeptide vaccine | |
| GB201003293D0 | Cancer vaccine | |
| WO2010034974A2 | Tuberculosis vaccines targeted to cd40 | |
| GB0910001D0 | TB vaccine | |
| GB0906555D0 | Tolerance | |
| GB0817480D0 | TB vaccine | |
| GB0806749D0 | Tolerance | |
| GB0707456D0 | Tolerance | |
| GB0703976D0 | Liposome preparation | |
| GB0607709D0 | Tolerance | |
| GB0507493D0 | Tolerance | |
| GB0408523D0 | Tolerance | |
| GB0401256D0 | Production of human antibodies | |
| GB0328206D0 | Adjuvant | |
| GB0327885D0 | Vaccine | |
| GB0308705D0 | Intolerance | |
| CA2509776A1 | Vaccine adjuvant based on a cd40 ligand | |
| GB0301433D0 | Protein adjuvant | |
| GB0228796D0 | Valency | |
| GB0228372D0 | Adjuvant |